Clinical trial

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

NCT04347226

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-04-16

PhasePHASE2

Study timeline

Study start (actual)2020-04-16Date precision: day

Registry last updated2025-05-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Solid Tumorunresolved

Sars-CoV2unresolved

Hematological Malignancyunresolved

Interventions

BMS-986253DRUG

Sponsors & collaborators

Columbia Universitylead sponsor

Bristol-Myers Squibbcollaborator

Mapped research locations

New YorkNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04347226 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.